ING Groep NV Cuts Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

ING Groep NV decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 5.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,163 shares of the medical research company’s stock after selling 1,355 shares during the period. ING Groep NV’s holdings in IQVIA were worth $5,489,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. PGGM Investments lifted its stake in IQVIA by 55.8% in the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock worth $2,553,000 after purchasing an additional 4,326 shares in the last quarter. Quadrature Capital Ltd purchased a new position in IQVIA during the 1st quarter valued at approximately $3,365,000. Raymond James & Associates increased its stake in IQVIA by 0.7% in the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock worth $169,231,000 after acquiring an additional 5,417 shares during the last quarter. UniSuper Management Pty Ltd raised its holdings in shares of IQVIA by 253.0% during the 1st quarter. UniSuper Management Pty Ltd now owns 6,029 shares of the medical research company’s stock worth $1,525,000 after acquiring an additional 4,321 shares in the last quarter. Finally, Versor Investments LP bought a new position in shares of IQVIA during the 3rd quarter valued at approximately $1,328,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Trading Down 5.1 %

Shares of IQV opened at $192.63 on Friday. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The firm has a market capitalization of $34.96 billion, a price-to-earnings ratio of 25.28, a PEG ratio of 2.17 and a beta of 1.51. The company has a 50-day moving average of $227.96 and a 200 day moving average of $228.59. IQVIA Holdings Inc. has a 1-year low of $189.63 and a 1-year high of $261.73.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on IQV shares. Morgan Stanley decreased their price target on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Redburn Atlantic started coverage on shares of IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 price target for the company. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research note on Friday, November 1st. BTIG Research lowered their price objective on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Finally, JPMorgan Chase & Co. cut their target price on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th. Five investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $259.13.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. This trade represents a 6.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.60% of the stock is currently owned by company insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.